Market Overview:
The global erythropoietin market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of anemia, kidney disorders, and other applications. The hospital segment is expected to dominate the market during the forecast period owing to rising demand for erythropoietin drugs for treating anemia and other complications in patients admitted in hospitals. In addition, growing awareness about erythropoietin therapy among clinicians is also propelling the growth of this market. However, stringent regulatory requirements are restraining the growth of this market. Geographically, North America dominates the global erythropoietin market followed by Europe and Asia Pacific respectively. This can be attributed to factors such as increasing prevalence of anemia and kidney disorders in these regions coupled with rising demand for better healthcare facilities.
Product Definition:
Epoetin-alfa erythropoietin is a hormone that stimulates the production of red blood cells by the bone marrow. It is used to treat anemia caused by kidney failure, cancer chemotherapy, or HIV infection.
Anemia:
Anemia is a condition wherein there is a decrease in the total amount of red blood cells or haemoglobin in the blood. Haemoglobin is an essential part of the red blood cell and binds oxygen. Anemia can be caused due to iron deficiency, vitamin B12 deficiency, chronic kidney disease, liver disease, chronic inflammation (rheumatoid arthritis), and cancer chemotherapy drugs.
Kidney Disorders:
The kidney is a vital organ located in the body. It helps in processing and removing waste products from the blood. Kidney disorders are caused when this organ does not work properly which can lead to various health problems such as high blood pressure, diabetes, and heart diseases.
Application Insights:
The market is segmented by application into hospital, clinic and others. The hospital segment dominated the overall industry in terms of revenue in 2017. This can be attributed to factors such as increasing prevalence of anemia and other blood disorders that require regular monitoring and treatment at hospitals. Increasing awareness about these treatments among patients suffering from anemia is also expected to drive demand over the forecast period.
The clinic application segment accounted for a significant share of the global epoetin-alfa erythropoietin market in 2017 owing to rising awareness about iron deficiency among adults coupled with growing adoption of this drug for non- indications related to iron deficiency or fatigue. For instance, many athletes are now using Epogen (epoetin alfa) as a replacement therapy for therapeutic use after they finish their course of chemotherapy or radiation therapy due largely fewer side effects associated with this drug when compared with other drugs used previously such as Aranesp (darbepoetin alfa).
Regional Analysis:
North America dominated the global epoetin-alfa market in terms of revenue with a share of over 40.0% in 2017. This is attributed to the presence of well-established healthcare facilities, high awareness levels coupled with relatively higher per capita income and availability of effective treatment methods for various blood disorders in this region as compared to other regions. Moreover, increasing R&D investments by major pharmaceutical companies for the development of novel products will boost market growth over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income.
Growth Factors:
- Increasing incidence of anemia: The increasing incidence of anemia is a major growth driver for the erythropoietin market. Anemia is a condition in which there is a deficiency of red blood cells or hemoglobin in the blood, resulting in symptoms such as fatigue, shortness of breath, and dizziness. According to the World Health Organization (WHO), an estimated 1.62 billion people were affected by anemia worldwide in 2013. This number is expected to increase to 1.84 billion by 2025 due to the growing population and rising prevalence of diseases such as cancer and HIV/AIDS that can lead to anemia.
- Rising demand for erythropoietin drugs: The increasing demand for erythropoietin drugs due to the growing prevalence of chronic kidney disease (CKD) is another major growth driver for the market. CKD is a progressive kidney disease that leads to loss of renal function over time and affects approximately 10%–15%of adults worldwide .The main cause of CKD is diabetes mellitus, followed by hypertension . As per estimates from Transparency Market Research (TMR),the global CKD therapeutics market was valued at US$ 7,898 million in 2016andis projectedto reachUS$ 15,252 millionby2025at acAGRof7%.This highgrowth rateis attributedtotheincreasingprevalenceofCKDis wellascontinuinginnovationinthether
Scope Of The Report
Report Attributes
Report Details
Report Title
Epoetin-alfa Erythropoietin Market Research Report
By Type
Anemia, Kidney Disorders, Other
By Application
Hospital, Clinic
By Companies
Amgen, Johnson & Johnson, Roche, Galenica, Emcure, Kyowa Hakko Kirin, 3SBio, Biocon, LG Life Sciences, Amgen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
136
Number of Tables & Figures
96
Customization Available
Yes, the report can be customized as per your need.
Global Epoetin-alfa Erythropoietin Market Report Segments:
The global Epoetin-alfa Erythropoietin market is segmented on the basis of:
Types
Anemia, Kidney Disorders, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Johnson & Johnson
- Roche
- Galenica
- Emcure
- Kyowa Hakko Kirin
- 3SBio
- Biocon
- LG Life Sciences
- Amgen
Highlights of The Epoetin-alfa Erythropoietin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anemia
- Kidney Disorders
- Other
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Epoetin-alfa Erythropoietin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Epoetin-alfa is a medication used to treat anemia. It works by increasing the number of red blood cells in the blood.
Some of the major companies in the epoetin-alfa erythropoietin market are Amgen, Johnson & Johnson, Roche, Galenica, Emcure, Kyowa Hakko Kirin, 3SBio, Biocon, LG Life Sciences, Amgen.
The epoetin-alfa erythropoietin market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Epoetin-alfa Erythropoietin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Epoetin-alfa Erythropoietin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Epoetin-alfa Erythropoietin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Epoetin-alfa Erythropoietin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Epoetin-alfa Erythropoietin Market Size & Forecast, 2020-2028
4.5.1 Epoetin-alfa Erythropoietin Market Size and Y-o-Y Growth
4.5.2 Epoetin-alfa Erythropoietin Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Anemia
5.2.2 Kidney Disorders
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Epoetin-alfa Erythropoietin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Epoetin-alfa Erythropoietin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Anemia
9.6.2 Kidney Disorders
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Anemia
10.6.2 Kidney Disorders
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Anemia
11.6.2 Kidney Disorders
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Anemia
12.6.2 Kidney Disorders
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Anemia
13.6.2 Kidney Disorders
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Epoetin-alfa Erythropoietin Market: Competitive Dashboard
14.2 Global Epoetin-alfa Erythropoietin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Johnson & Johnson
14.3.3 Roche
14.3.4 Galenica
14.3.5 Emcure
14.3.6 Kyowa Hakko Kirin
14.3.7 3SBio
14.3.8 Biocon
14.3.9 LG Life Sciences
14.3.10 Amgen
